Abstract:Aim To apply model-informed drug development (MIDD) approach to support the decision making in drug development and accelerate the clinical development of janagliflozin, an orally selective SGLT2 inhibitor. Method We previously developed a mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model of janagliflozin based on preclinical data to optimize dose design in the first-in-human (FIH) study. In the current study, we used clinical PK/PD data of the FIH study to validate the model and then simulate the PK/PD profiles of multiple ascending dosing (MAD) study in healthy subjects. Besides, we developed a population PK/PD model of janagliflozin to predict steady-state urinary glucose excretion (UGE [UGE,ss]) in healthy subjects in the Phase 1 stage. This model was subsequently used to simulate the UGE, ss in patients with type 2 diabetes mellitus (T2DM) based on a unified PD target (ΔUGEc) across healthy subjects and patients with T2DM. This unified PD target was estimated from our previous work of model-based meta-analysis (MBMA) for the same class of drugs. The model-simulated UGE,ss in patients with T2DM was validated by data from the clinical Phase 1e study. Finally, at the end of the Phase 1 study, we simulated the 24-week hemoglobin A1c (HbA1c) level in patients with T2DM of janagliflozin based on the quantitative UGE/FPG/HbA1c relationship informed by our previous MBMA study for the same class of drugs. Results The pharmacologically active dose (PAD) levels of multiple ascending dosing (MAD) study were estimated to be 25, 50,100 mg once daily (QD) for 14 days based on the effective PD target of approximately 50 g daily UGE in healthy subjects. Besides, our previous MBMA analysis for the same class of drugs has provided a unified effective PD target of ΔUGEc approximately 0.5–0.6 g/(mg/dL) in both healthy subjects and patients with T2DM. In this study, the model-simulated steady-state ΔUGEc (ΔUGEc,ss) of janagliflozin in patients with T2DM were 0.52, 0.61 and 0.66 g/(mg/dL) for 25, 50, 100 mg QD dose levels. Finally, we estimated that HbA1c at 24 weeks would decrease 0.78 and 0.93 from baseline for the 25 and 50 mg QD dose groups. Conclusions The application of MIDD strategy adequately supported the decision making at each stage of janagliflozin development process. A waiver of Phase 2 study was successfully approved for janagliflozin based on these model-informed results and suggestions. This MIDD strategy of janagliflozin could be further utilized to support the clinical development of other SGLT2 inhibitors.

Limited Sampling Strategy Models for Estimating the AUC of Gliclazide in Chinese Healthy Volunteers

Limited Sampling Strategy Models for Estimating AUC for Amlodipine in Chinese Healthy Volunteers

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Evaluation of the Area under the Curve of Enteric-Coated Mycophenolate Sodium Using a Limited Sampling Strategy in Chinese Kidney Transplant Recipients .

Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals

Pharmacokinetics of Ginsenosides Rg1, Re and Notoginsenoside R1 in Rats by an in vivo Microdialysis Coupled with Liquid Chromatography/Mass Spectrometry

Limited Sampling Strategy for Predicting the Area under Plasma Concentration–Time Curve of Nadolol in Healthy Subjects

Limited Sampling Strategies for Clinical Plasma Concentration Monitoring of Mycophenolic Acid

Monitoring Plasma Concentrations of Mycophenolic Acid in Patients with Renal Transplantation by Limited Sampling Strategy

A simulation study of sampling time point designing for therapeutic drug monitoring based on a population pharmacokinetic model

Estimation of Mycophenolic Acid Area under the Curve with Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach

Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy

Bioequivalence evaluation of two formulations of pidotimod using a limited sampling strategy.

1295-P: Economic Evaluation of Drug Combination Strategy for Type 2 Diabetes in China

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

A Sensitive LC/MS/MS Method for the Determination of Glycyrrhetic Acid in Human Plasma and Application to Pharmacokinetic Study

A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor

Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion

Limited sampling approach for model‐informed precision dosing of daptomycin to rapidly achieving the target area under the concentration‐time curve: A simulation study

The effect of different sampling time on dual-plasma-sample method in determination of iohexol clearance